Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Impact of MRD on FLT3-ITD AML

Mark Levis • 1 Dec 2018
ASH 2018
Acute Myeloid Leukemia Leukemia Gilteritinib
RATIFY

The predictive role of measurable residual disease (MRD) on survival across the hematology-oncology space is under intense investigation. Here, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the impact of MRD on FLT3-ITD acute myeloid leukemia (AML). Dr Levis highlights how measuring MRD, using an NGS-based assay, revealed a potential association between MRD negativity and longer survival in patients with relapsed/refractory FLT3-ITD AML. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Mark Levis

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:03
Personalizing AML treatment by targeting MRD mutations
Mark Levis • 10 Dec 2023
2:00
FLT3-ITD-specific MRD predicts outcomes of chemotherapy in AML
Mark Levis • 10 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals